
|Articles|February 12, 2020
NUVISAN and Bayer Create New Research Unit in Berlin
Advertisement
NUVISAN has agreed with Bayer to integrate large parts of Bayer’s Berlin-based small molecule research unit and complements hereby its services in the field of preclinical research. The strategic partnership will lay the foundation for a new research entity to be established by the two companies. The transaction is expected to close mid 2020.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Honing the Power of AI for Next Generation Trial Oversight and Execution
2
ACT Brief: AI-Driven Oversight, Biotech Acceleration Strategies, and a Major Win in Bladder Cancer
3
Genentech’s Phase III MEERKAT and SANDCAT Trials Show Vision and Anatomical Gains With Vamikibart in Uveitic Macular Edema
4
AstraZeneca’s Phase III POTOMAC Trial Shows Imfinzi Significantly Improves Disease-Free Survival in High-Risk NMIBC
5